- $20.64bn
- $3.24bn
- €3.82bn
- 92
- 80
- 16
- 66
Annual balance sheet for BioNTech SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 521 | 1,347 | 2,074 | 14,065 | 16,549 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 20.2 | 171 | 12,382 | 7,146 | 2,340 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 560 | 1,667 | 15,072 | 21,922 | 19,527 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 148 | 326 | 520 | 821 | 972 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 798 | 2,319 | 15,831 | 23,279 | 23,006 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 138 | 606 | 3,482 | 2,951 | 2,071 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 304 | 947 | 3,937 | 3,224 | 2,760 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 493 | 1,372 | 11,894 | 20,056 | 20,246 |
| Total Liabilities & Shareholders' Equity | 798 | 2,319 | 15,831 | 23,279 | 23,006 |
| Total Common Shares Outstanding |